Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: Developed by Eli Lilly and Co's (LLY.N) Loxo Oncology and marketed by German drugmaker Bayer (BAYGn.DE), it fights a rare genetic mutation that appears in less than 1% of solid tumors, regardless of where they appear in the body. Finding those patients will require widespread adoption of sophisticated tests that look for multiple genetic alterations that could be driving the cancer. So far, progress has been slow. Adoption of so-called next-generation sequencing (NGS) tests has been stalled by lack of reimbursement from insurers over concerns that the evidence is not there yet to support widescale use, according to more than a dozen interviews with oncologists and pharmaceutical and diagnostic industry executives. As a result, pharma companies from small biotech Blueprint Medicines Corp (BPMC.O) to larger rivals Lilly and Roche Holding AG (ROG.S) are taking matters into their own hands, bulking up staff to increase patient and physician awareness about testing and building up a gene testing infrastructure that for many community hospitals still does not exist. Bayer executives told Reuters it plans to spend $70 million to increase patient and physician awareness of testing for rare mutations and to encourage regulatory approval of more tests. They expect that budget to expand as Vitrakvi continues to win approval in other countries. Lilly told Reuters the company has signed an agreement with Thermo Fisher Scientific (TMO.N) to develop a companion diagnostic test for its experimental drug, LOXO-292. The deal adds RET mutations - the target of both Lilly's and Blueprint's drugs - to Thermo's Oncomine Dx Target Test, which local pathology labs can use to identify multiple genes linked with non-small cell lung cancer. The agreement is aimed to help identify more lung and thyroid cancer patients who may benefit from the Lilly or Blueprint therapies. The Thermo test is already approved by the U.S. Food and Drug Administration - a key standard for Medicare coverage, the companies said. According to Dr. Brian Alexander, chief medical officer of Roche's gene testing company Foundation Medicine, only about 15% of U.S. patients with advanced cancers get comprehensive genomic profiling. Another 25% get single-gene testing, he said, and a large proportion "are not getting any testing at all." At MD Anderson, which sees 100,000 new cancer patients a year, only around 10,000 eventually have their tumors sequenced. For a rare few, the tests are lifesaving. Xin Zheng, 47, a mother of three in Michigan who was referred to Reuters by Blueprint, was diagnosed with stage 4 lung cancer in 2016. After failing several treatments, she was out of options. Her husband, Zhigang Wei, asked for genetic sequencing, and the test turned up a RET mutation. After contacting multiple lung cancer experts, Zhigang found an early-stage clinical trial treating patients with Blueprint's experimental drug, BLU-677. Now, Xin is nearly back to normal. "My wife is lucky,"he said, adding her quality of life is much better and she has hope for the future. Finding patients with such rare mutations is like "looking for the needle in the haystack," said Stefan Oelrich, head of pharmaceuticals at Bayer. Dr. David Hyman of Memorial Sloan Kettering Cancer Center, who tested Vitrakvi in clinical trials, said making these tests the norm for advanced cancer patients will require a huge shift in the way oncology is practiced. "It's painful to know there are patients out there with these alterations who are dying without knowing about it and without getting any treatments," he said. For Bayer's Vitrakvi and Roche's Rozlytrek, along with similar drugs in development, genomic testing is critical to finding patients who can benefit from them. Cancer patients and drug companies alike got a boost last year when the federal Medicare health program for the elderly and disabled said it would cover FDA-approved tests for advanced cancer patients that can identify hundreds of genetic mutations at once. A Medicare endorsement is generally followed by widespread coverage decisions by private insurers. But the final regulations dropped a requirement that testmakers prove the tests are cost-effective and improve patient care. That created an "evidence gap" that has allowed some insurers, also known as third-party payers, to withhold coverage or demand more proof that they benefit patients, said Jeff Schreier of Diaceutics PLC (DXRX.L), a data analytics company that works with drugmakers to improve diagnostic testing. "More payers are coming around, but it's slow," he said. The most recent coverage policy from CVS Health Corp's (CVS.N) Aetna approves many single-gene tests for specific cancers, but still largely considers multi-gene tests experimental. Anthem Inc's (ANTM.N) policy limits testing to "medically necessary" use and states there's "insufficient published evidence" to support widespread testing. And while Foundation Medicine's and Thermo Fisher's tests are getting reimbursed from Medicare, many hospitals such as MD Anderson, which have developed their own tests, are not guaranteed payment. "Reimbursement is still a driving force," MD Anderson's Kenna Shaw said of genomic testing, which costs an average of $5,000 per patient globally. Lilly bought Loxo in January for $8 billion to profit from its targeted drugs in early-stage development. Bayer secured the rights to Loxo's two leading compounds in a 2017 alliance. Dr. Anthony Sireci, Loxo's senior medical director, said the company has been working to "democratize" testing in the United States by increasing its use in local pathology labs, where most cancer testing has traditionally been done. The Thermo Fisher agreement will support those goals and expand patients' access to "high-quality genomic testing," he said. Bayer has hired diagnostic experts to help its medical and sales staff assess the barriers to genomic testing and ensure that local pathology labs are including the genetic alterations targeted by its drugs when they profile tumors, the company's oncology strategic business chief Robert LaCaze said in an interview. Bayer also launched a public awareness campaign called "Test Your Cancer" that urges patients to ask their doctors about genomic cancer testing. The company is working with testing providers to ensure test reports are easy to understand. Blueprint, which has six genomically-targeted drugs in development, told Reuters it plans to hire six diagnostics experts to increase awareness of the mutations their drugs target, especially in community medical practices, where 70% of cancers are treated. Bayer sees signs of progress. Based on internal data, the company estimates average sequencing rates across tumors neared 30% last year, and the company saw a two-fold increase in the number of labs offering tests that carry the mutation targeted by Vitrakvi. Bayer has not released sales figures for Vitrakvi. Asked for an update in the most recent earnings call in July, Bayer's Oelrich said uptake is going "according to plan," but declined to say how many patients are using the drug. LaCaze said with very rare cancers like the ones Vitrakvi targets, sales growth is "something that will build over time."
[EX A]: Inside drugmakers' strategy to boost cancer medicines with 'Lazarus effect'.

[EX Q]: The verdict in the lawsuit brought by the California woman, Eva Echeverria, marks the largest sum awarded in a series of talcum powder lawsuit verdicts against Johnson & Johnson in courts around the U.S. Echeverria alleged Johnson & Johnson failed to adequately warn consumers about talcum powder's potential cancer risks. She used the company's baby powder on a daily basis beginning in the 1950s until 2016 and was diagnosed with ovarian cancer in 2007, according to court papers. Echeverria developed ovarian cancer as a "proximate result of the unreasonably dangerous and defective nature of talcum powder," she said in her lawsuit. Echeverria's attorney, Mark Robinson, said his client is undergoing cancer treatment while hospitalized and told him she hoped the verdict would lead Johnson & Johnson to put additional warnings on its products. "Mrs. Echeverria is dying from this ovarian cancer and she said to me all she wanted to do was to help the other women throughout the whole country who have ovarian cancer for using Johnson & Johnson for 20 and 30 years," Robinson said. "She really didn't want sympathy," he added. "She just wanted to get a message out to help these other women." The jury's award included $68 million in compensatory damages and $340 million in punitive damages, Robinson said. The evidence in the case included internal documents from several decades that "showed the jury that Johnson & Johnson knew about the risks of talc and ovarian cancer," Robinson said. "Johnson & Johnson had many warning bells over a 30 year period but failed to warn the women who were buying its product," he said. Johnson & Johnson spokeswoman Carol Goodrich said in a statement that the company will appeal the jury's decision. She says while the company sympathizes with women suffering from ovarian cancer that scientific evidence supports the safety of Johnson's baby powder. The verdict came after a St. Louis, Missouri jury in May awarded $110.5 million to a Virginia woman who was diagnosed with ovarian cancer in 2012. She had blamed her illness on her use of the company's talcum powder-containing products for more than 40 years. Besides that case, three other trials in St. Louis had similar outcomes last year with juries awarding damages of $72 million, $70.1 million and $55 million, for a combined total of $307.6 million. Another St. Louis jury in March rejected the claims of a Tennessee woman with ovarian and uterine cancer who blamed talcum powder for her cancers. Two similar cases in New Jersey were thrown out by a judge who said the plaintiffs' lawyers did not presented reliable evidence linking talc to ovarian cancer. More than 1,000 other people have filed similar lawsuits. Some who won their lawsuits won much lower amounts, illustrating how juries have wide latitude in awarding monetary damages. Johnson & Johnson is preparing to defend itself and its baby powder at upcoming trials in the U.S., Goodrich said. ___ Associated Press writer Amanda Lee Myers contributed to this report. ___ Follow Michael Balsamo on Twitter at http://twitter.com/MikeBalsamo1 .
[EX A]: Record $417M award in lawsuit linking baby powder to cancer.

[EX Q]: The company's internal "marketing standards" prohibit it from promoting tobacco products with youth-oriented celebrities or "models who are or appear to be under the age of 25." The company told Reuters of the decision late Friday, saying it had launched an internal investigation into marketing posts and photographs that Reuters sent to the company for comment earlier this week. They included a paid post plugging the tobacco product by social media "influencer" Alina Tapilina in Moscow - who listed her age as 21 on Instagram - alongside often seductive photos of herself drinking wine, swimming and posing with little clothing in luxurious settings. "We have taken the decision to suspend all of our product-related digital influencer actions globally," the company told Reuters. "Whilst the influencer in question is a legal age adult smoker, she is under 25 and our guidance called for influencers to be 25+ years of age. This was a clear breach of that guidance." "No laws were broken," the company told Reuters. "However, we set high standards for ourselves and these facts do not excuse our failure to meet those standards in this instance." The company added: "We were deeply disappointed to discover this breach and are grateful that it was brought to our attention." The U.S. Food and Drug Administration (FDA) last month decided it would allow sales of the IQOS device in the United States after a two-year review process in which Philip Morris repeatedly assured the regulator that it would warn young people away from the product. The FDA declined to comment Friday evening on Philip Morris's decision to suspend the marketing campaign. The agency earlier said it would "keep a close watch on ... how the company is marketing its products." While most of the social media influencers hired by Philip Morris overseas did not list their ages on Instagram, a Reuters review of the firm's social media marketing of IQOS in Japan, Italy, Switzerland, Russia and Romania shows that Tapilina's online persona was typical of what the company called its social media "ambassadors" for the device - rail-thin young women who revel in the high life. The company did not directly respond to additional questions Friday night regarding the intended audience for its digital influencer campaigns. Many of the messages contained the hashtag "#IQOSambassador," tying them into a network of social media influencers that the international tobacco giant has relied on to brand the IQOS as a safer alternative to cigarettes and a sexy fashion accessory. "I finally have the new IQOS 3, and I can confidently say yes to change the level of harmful substances is on average about 90 percent lower than in smoke," Tapilina wrote in an April post. "You haven't yet switched to IQOS?" One Romanian IQOS marketer is 25 years old, according to a separate actress biography, but did not list her age on Instagram. Tapilina and nine other IQOS marketers did not respond to requests for comment. Philip Morris, in its statement to Reuters, said its suspension of the social marketing campaign is "concrete proof" of its "conviction to achieve a smoke-free world through socially responsible practices." Matthew Myers, president of The Campaign for Tobacco-Free Kids, had a different take upon hearing of the suspension Friday night. The advocacy group collected some of the IQOS marketing images reviewed by Reuters. Philip Morris, he said, "is changing their behavior only when caught red-handed." The company, Myers said, has historically been "the single most successful across the globe in making cigarettes fashionable to young people." Over the past year, Philip Morris has increasingly publicized its "mission" to prevent young people from using tobacco products. Last month, it issued a release calling on "all tobacco and e-cigarette companies to do their part to guard against youth nicotine use." "Let me be clear: We at Philip Morris International do not, and will not, market or sell our products to youth," CEO Andre Calantzopoulos said during a speech in Boston earlier this month. "For Philip Morris International, age matters." When Philip Morris submitted marketing plans with an FDA application for IQOS in 2017, its sample advertisements featured models appearing at least a decade older and wearing modest, professional clothes. That application, which is still pending before the FDA, seeks approval to market the IQOS as less harmful than smoking and outlines company plans to ensure it doesn't market the device to "non-intended audiences." The device heats up but does not burn packages of ground-up tobacco, which resemble small cigarettes, to create a nicotine-filled aerosol. In Japan, the intended audience for IQOS marketing includes the Instagram followers of Ayame Tachibana, a 27-year-old DJ and model. In one post, she shows off a Valentine's Day message for the IQOS device, lovingly scrawled with multicolored pens. "Happy Valentine IQOS. Love you sooo much!" reads the Instagram post from February. Alina Eremia, a Romanian actress and singer, holds a gold-colored IQOS in front of a Christmas tree. "My list of resolutions contains 95% fewer moments without a smile," says Eremia, who is 25 according to her actress biography on multiple movie and celebrity information websites. Philip Morris says the IQOS - an acronym for "I quit ordinary smoking" contains up to 95 percent fewer toxic compounds than cigarettes. Vlad Parvulescu, a manager for Eremia, confirmed she had been hired to promote IQOS and said she had been contacted by a Romanian public relations agency. He did not respond to additional questions about the financial arrangement. Marketing deals between companies and social media influencers vary widely, according to industry experts. But typically a company will work through third-party public relations or advertising firms that have relationships with online personalities. Compensation typically ranges from $20 to $25,000 or more for each post. Corporations have become increasingly sophisticated in how they approach their social media campaigns in the past two years, said Joe Gagliese, co-founder of Viral Nation, a marketing and talent agency that works with influencers. He once had to explain the basic concept of an "influencer" in pitch meetings. Now, companies approach him with "tailor-made decision briefs saying, 'this is exactly what we want.'" Reuters reviewed dozens of social media posts featuring the IQOS device. Many included hashtags such as #IQOSAmbassador, #paidad, and #notriskfree, indicating that they are IQOS marketing posts. Many of the Instagram influencers featuring the products had tens of thousands of followers, and a few had more than a million. Devices such as IQOS and Juul hold potential as a way for cigarette smokers to transition to less harmful nicotine products, but some public health advocates worry the sleek new devices are addicting young people who would have never smoked cigarettes. Among traditional cigarette smokers, 90 percent start smoking before the age of 18, according to federal data. Philip Morris said there have been "no reports" of "worrisome levels" of unintended use of IQOS. As part of the FDA review process, Philip Morris pledged to market only to adult cigarette smokers once it begins selling IQOS this summer through a partnership with Altria Group Inc, which sells Marlboro cigarettes in the U.S. IQOS delivers about the same level of nicotine as a traditional cigarette. Altria did not respond to requests for comment. Social media marketing has become a flashpoint in the debate over regulation of tobacco products, particularly the newest generation of products such as the wildly popular Juul e-cigarettes. Some of Juul's early social media and YouTube marketing included images of attractive young people, particularly at a 2015 product launch party. Twitter images from that time on Juul's official account featured sensual images of a young woman breathing out Juul vapor in a group, next to the slogan, "Share a #Juulmoment." Those early campaigns sparked an explosion of video and photo posts from young people showing themselves using the product at school or with friends, often under the hashtags #doit4juul or #juullife. Juul Labs Inc has since said it stopped using social media influencers and requires anyone in its ads to be a former cigarette smoker older than 35. Juul Labs Inc said in a statement it recognizes that "some of our earliest marketing initiatives did not fully reflect the goal of our company," which it describes as helping cigarette smokers transition to its products. "As a young company, we learned from our experiences and instituted changes to help ensure that we are only reaching current adult smokers," the company said. U.S. laws governing tobacco advertising - which is banned on radio and television - were drawn up long before social media and digital advertising became a dominant force in consumer marketing. Although no current state or federal law restricts tobacco advertising on the Internet - including for e-cigarettes and devices such as IQOS - the FDA can use its authority over new devices to assert sweeping control over a company's marketing. As a condition for allowing the device to be sold, the FDA is requiring Philip Morris to provide detailed analyses of the age ranges of consumers it reaches through digital advertising. Philip Morris is also required to submit any new advertising campaigns, including digital and social media efforts, to the FDA at least 30 days before it plans to launch them. Any paid influencers promoting the product also must disclose "any relationships between you and entities that create labeling for, advertise, market, and/or promote the products, on your behalf, or at your direction." Those rules aim to restrict youth access to tobacco marketing, the FDA said in a statement, "especially in shared digital properties such as social media sites."
[EX A]:
Exclusive: Philip Morris suspends social media campaign after Reuters exposes young 'influencers'.